Richard Ong

546 total citations
20 papers, 413 citations indexed

About

Richard Ong is a scholar working on Molecular Biology, Hepatology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Richard Ong has authored 20 papers receiving a total of 413 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Hepatology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Richard Ong's work include Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Gastric Cancer Management and Outcomes (4 papers) and Cancer Mechanisms and Therapy (3 papers). Richard Ong is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (7 papers), Gastric Cancer Management and Outcomes (4 papers) and Cancer Mechanisms and Therapy (3 papers). Richard Ong collaborates with scholars based in Singapore, United States and Switzerland. Richard Ong's co-authors include Hung Huynh, Khee Chee Soo, Pierce K. H. Chow, Alan Huang, Dieter Zopf, Alexander Yaw Fui Chung, Youzhen Wang, David A. Ruddy, Robert Schlegel and Xiaoyan Li and has published in prestigious journals such as Journal of Clinical Oncology, Hepatology and Cancer Research.

In The Last Decade

Richard Ong

18 papers receiving 411 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Richard Ong Singapore 9 207 116 110 94 84 20 413
Toshiro Ogura Japan 11 206 1.0× 270 2.3× 162 1.5× 94 1.0× 140 1.7× 45 554
Inge Ubink Netherlands 14 145 0.7× 241 2.1× 86 0.8× 44 0.5× 97 1.2× 19 459
Ruixuan Geng China 12 234 1.1× 254 2.2× 196 1.8× 30 0.3× 148 1.8× 29 556
Wataru Yasui Japan 10 266 1.3× 194 1.7× 120 1.1× 141 1.5× 73 0.9× 10 561
Aikseng Ooi Japan 10 327 1.6× 276 2.4× 210 1.9× 46 0.5× 89 1.1× 18 654
Mariantonietta Di Salvatore Italy 13 140 0.7× 276 2.4× 159 1.4× 37 0.4× 110 1.3× 36 473
Maria Alessandra Calegari Italy 10 89 0.4× 220 1.9× 109 1.0× 31 0.3× 70 0.8× 43 361
F. De Vita Italy 11 198 1.0× 405 3.5× 196 1.8× 50 0.5× 220 2.6× 37 691
Masahiko Matsuda Japan 7 290 1.4× 356 3.1× 256 2.3× 132 1.4× 54 0.6× 13 664

Countries citing papers authored by Richard Ong

Since Specialization
Citations

This map shows the geographic impact of Richard Ong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Ong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Ong more than expected).

Fields of papers citing papers by Richard Ong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Richard Ong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Ong. The network helps show where Richard Ong may publish in the future.

Co-authorship network of co-authors of Richard Ong

This figure shows the co-authorship network connecting the top 25 collaborators of Richard Ong. A scholar is included among the top collaborators of Richard Ong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Richard Ong. Richard Ong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Teo, Pei Y., David H. Quach, Richard Ong, et al.. (2024). Overexpression of an Engineered SERPINB9 Enhances Allogeneic T-cell Persistence and Efficacy. Cancer Immunology Research. 12(8). 1108–1122. 1 indexed citations
2.
Ng, Chee H., Cheah C. Seh, Richard Ong, et al.. (2024). Novel OX40 and 4-1BB derived spacers enhance CD30 CAR activity and safety in CD30 positive lymphoma models. Molecular Therapy. 32(10). 3504–3521. 3 indexed citations
3.
Huynh, Hung, Richard Ong, Kah Yong Goh, et al.. (2019). Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β‑catenin pathway in xenograft models of hepatocellular carcinoma. International Journal of Oncology. 54(3). 1123–1133. 18 indexed citations
4.
Huynh, Hung, Kah Yong Goh, Richard Ong, et al.. (2018). Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma. Hepatology. 69(3). 943–958. 53 indexed citations
5.
Huynh, Hung, Richard Ong, Florian Puehler, et al.. (2016). Abstract 2276: Sorafenib/Refametinib potently inhibits Wnt/β-catenin in vitro and patient-derived xenograft models of human hepatocellular carcinoma. Cancer Research. 76(14_Supplement). 2276–2276. 2 indexed citations
6.
Ooi, Aikseng, et al.. (2016). Abstract 4719: Varlitinib demonstrates potent antitumor efficacy in patient-derived gastric cancer xenograft models. Cancer Research. 76(14_Supplement). 4719–4719. 2 indexed citations
7.
Ong, Richard, et al.. (2016). Varlitinib to demonstrate anti-tumour efficacy in patient-derived hepatocellular carcinoma xenograft models.. Journal of Clinical Oncology. 34(15_suppl). e15598–e15598. 3 indexed citations
8.
Huynh, Hung, Huai-Xiang Hao, Stephen L. Chan, et al.. (2015). Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus. Molecular Cancer Therapeutics. 14(5). 1224–1235. 60 indexed citations
9.
Li, Fang, Hung Huynh, Xiaoyan Li, et al.. (2015). FGFR-Mediated Reactivation of MAPK Signaling Attenuates Antitumor Effects of Imatinib in Gastrointestinal Stromal Tumors. Cancer Discovery. 5(4). 438–451. 85 indexed citations
10.
Huynh, Hung, Richard Ong, & Dieter Zopf. (2015). Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer. Journal of Experimental & Clinical Cancer Research. 34(1). 132–132. 36 indexed citations
11.
12.
Huynh, Hung, Richard Ong, Mei Ling Chong, et al.. (2015). Abstract 2674: Activity of BAY1082439, a balanced PI3Kα/β inhibitor, in gastric cancer. Cancer Research. 75(15_Supplement). 2674–2674.
13.
Yuen, John Shyi Peng, Hong Gee Sim, Tsung Wen Chong, et al.. (2012). Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma. International Journal of Oncology. 41(2). 712–720. 27 indexed citations
14.
Hartono, Septian, Tong San Koh, Quan Sing Ng, et al.. (2012). Abstract 1317: Dose-dependent effects of bevacizumab on human HCC xenografts. Cancer Research. 72(8_Supplement). 1317–1317. 1 indexed citations
15.
Huynh, Hung, Pierce K. H. Chow, Su Pin Choo, et al.. (2011). Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma. Journal of Hepatology. 56(3). 595–601. 48 indexed citations
16.
Huynh, Hung, Su Pin Choo, Wai Meng David Tai, et al.. (2011). Comparing the Efficacy of Sunitinib with Sorafenib in Xenograft Models of Human Hepatocellular Carcinoma: Mechanistic Explanation. Current Cancer Drug Targets. 11(8). 944–953. 14 indexed citations
17.
Huynh, Hung, Richard Ong, Khee Chee Soo, Oliver Politz, & Dieter Zopf. (2011). Abstract B2: Regorafenib, an oral multi-kinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases, potently inhibits tumor growth and angiogenesis in patient-derived xenograft models of gastric cancer.. Molecular Cancer Therapeutics. 10(11_Supplement). B2–B2. 2 indexed citations
18.
19.
Huynh, Hung, Richard Ong, & Khee Chee Soo. (2011). Foretinib demonstrates anti-tumor activity and improves overall survival in preclinical models of hepatocellular carcinoma. Angiogenesis. 15(1). 59–70. 51 indexed citations
20.
Yang, Chuen‐Mao, et al.. (1995). Inhibitory effect of phorbol ester on carbachol-induced signal transduction in cultured canine tracheal smooth muscle cells. Journal of Biomedical Science. 2(3). 283–292. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toshiro Ogura Breakdown of academic impact, for papers by Inge Ubink Breakdown of academic impact, for papers by Ruixuan Geng Breakdown of academic impact, for papers by Wataru Yasui Breakdown of academic impact, for papers by Aikseng Ooi Breakdown of academic impact, for papers by Mariantonietta Di Salvatore Breakdown of academic impact, for papers by Maria Alessandra Calegari Breakdown of academic impact, for papers by F. De Vita Breakdown of academic impact, for papers by Masahiko Matsuda
Rankless by CCL
2026